CVS Health said an analysis of Aetna insurance data found that GLP-1 medicines used to treat obesity and diabetes could allow employers and health plans to break even if the drugs were priced at less than $350 per month. The findings place the cost of these medicines at the center of an expanding debate over coverage, affordability and medical spending.
The analysis linked GLP-1 treatment with lower use of costly medical services over a three-year period. CVS said emergency-room visits fell by 10% to 12%, while hospitalizations declined by as much as 42%. Those reductions could generate savings for insurers and employers that pay for health care, potentially offsetting the cost of covering the medicines at a sufficiently low price.
Potential savings have not offset current prices
CVS said the prices currently paid by health plans remain too high to compensate for the medical savings identified in the analysis. As a result, broader use of GLP-1 medicines is increasing overall spending for plans rather than producing a break-even outcome.
The company is urging drugmakers to reduce prices. CVS said lower prices could improve affordability for patients while also helping employers and health plans manage their medical costs. The issue has become more pressing as some companies have dropped coverage for GLP-1 medicines because rising premiums have made the benefit more difficult to sustain.
| Measure | Finding in CVS analysis |
|---|---|
| Price threshold for break-even coverage | Below $350 per month |
| Reduction in emergency-room visits | 10% to 12% |
| Reduction in hospitalizations | Up to 42% |
| Period examined | Three years |
What the analysis means for coverage
GLP-1 medicines are used for obesity and diabetes, conditions that can require substantial medical care. CVS’s analysis suggests that the financial case for coverage depends on more than the pharmacy price alone: fewer emergency visits and hospital stays can reduce other costs, but those savings must be large enough to offset the price paid for the medicines.
The company’s position reflects a tension facing health plans. Covering the drugs can expand access to treatment, but the immediate pharmaceutical expense may exceed savings elsewhere in the health system. CVS said a lower price would be needed for the reductions in hospital and emergency care identified in the Aetna data to bring plans to a break-even point.
- CVS analyzed data from Aetna, its insurance business.
- The analysis covered a three-year period.
- CVS said current prices paid by plans are above the level needed to offset the reported savings.
The analysis does not represent a change in coverage policy or a new drug-price agreement. Instead, it presents CVS Health’s assessment of the price level at which the medical savings associated with GLP-1 treatment could balance spending by employers and health plans. The company’s findings also do not establish that every plan or patient would experience the same results.